Interestingly, we have also demonstrated how a MEK1/2 inhibitor can modulate the immunosuppressive tumor microenvironment of KRAS-mutant lung adenocarcinoma (LUAD) tumors though Id1 downregulation (unpublished data). The gene discussed is ID1; the disease is neoplasm.